We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




CSF Pleocytosis Level Investigated as Diagnostic Predictor

By LabMedica International staff writers
Posted on 13 Sep 2017
Migration of leukocytes to the cerebrospinal fluid is a cardinal symptom of an infectious condition affecting the meninges or the cerebral parenchyma. More...
Bacterial and viral meningitis cannot reliably be differentiated clinically and requires lumbar puncture to analyze the cerebrospinal fluid.

Lumbar puncture with quantification of leukocytes and differential count of cellular subsets in the cerebrospinal fluid is a standard procedure in cases of suspected neuroinfectious conditions. However, a number of non-infectious causes may result in a low leukocyte number. Pleocytosis is an increased cell count, particularly an increase in white blood cell count, in a bodily fluid, such as cerebrospinal fluid. It is often defined specifically as an increased white blood cell count in cerebrospinal fluid.

Scientists at the Odense University Hospital (Odense, Denmark) and their academic colleagues based their study on data from cerebrospinal fluid (CSF) analyses of all adult patients (15 years or older) admitted to a large university hospital in Denmark during a two-year period (2008–2009). Out of 5,390 unselected cerebrospinal fluid samples, 262 met the inclusion criteria. The neurological department (56.5%), department of emergency admission (14.9%), and the department of intensive care (7.3%) were the main contributors to CSF analyses.

In 141 patients mean CSF/plasma glucose ratio was 0.6 (normal). Significantly lower CSF/plasma glucose ratio was found in the decreased interval (less than 0.46) for CNS infection (mean = 0.2). Significant higher CSF/plasma glucose ratio was found in the decreased interval (less than 0.46) for non-infectious neurological diseases (mean = 0.4). Pleocytosis of greater than five leucocytes/μL was found in samples from 262 patients of which 106 (40.5%) were caused by infection of the central nervous system (CNS), 20 (7.6%) by infection outside CNS, 79 (30.2%) due to non-infectious neurological diseases, 23 (8.8%) by malignancy, and 34 (13.0%) caused by other conditions. Significantly higher mean CSF leukocytes were found in patients suffering from CNS infection (mean = 1,135 cells/μL).

The authors concluded that CNS infection, non-infectious neurological disease, malignancy, and infection outside CNS can cause pleocytosis of the cerebrospinal fluid. Leukocyte counts above 100/μL is mainly caused by CNS infection, whereas the number of differential diagnoses is higher if the CSF leukocyte counts is below 50/μL. These conditions are most commonly caused by non-infectious neurological diseases including seizures.

Related Links:
Odense University Hospital


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.